Zacks Research Issues Positive Outlook for FOLD Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities researchers at Zacks Research lifted their Q2 2027 EPS estimates for Amicus Therapeutics in a research report issued to clients and investors on Wednesday, July 9th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.10 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share.

Several other brokerages also recently commented on FOLD. UBS Group raised their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, The Goldman Sachs Group decreased their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Stock Up 2.5%

Shares of FOLD traded up $0.15 during trading hours on Friday, reaching $6.24. 2,327,993 shares of the stock traded hands, compared to its average volume of 3,797,046. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. The stock has a fifty day simple moving average of $6.07 and a 200 day simple moving average of $7.76. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -69.33 and a beta of 0.51.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its holdings in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares during the period. Nuveen LLC acquired a new stake in Amicus Therapeutics in the 1st quarter worth about $28,741,000. Vestal Point Capital LP acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $31,557,000. Norges Bank acquired a new stake in shares of Amicus Therapeutics in the fourth quarter valued at about $29,033,000. Finally, Assenagon Asset Management S.A. boosted its position in Amicus Therapeutics by 641.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company's stock worth $20,249,000 after acquiring an additional 3,057,072 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.